Streetbeat News

Products Services

XLO

Xilio Therapeutics announced initial monotherapy safety and anti-tumor activity data for XTX202, a tumor-activated, engineered, Beta-Gamma IL-2, in late line patients with advanced solid tumors. The treatment showed a 50% disease control rate at higher doses and 31% across all dose levels. Adverse events were primarily Grade 1-2 at doses up to 4 mg/kg. Two patients have been on the treatment for over a year, indicating good tolerance. Xilio plans to evaluate XTX202 in a Phase 2 trial in patients with advanced melanoma and renal cell carcinoma.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:12 pm

SGEN

Seagen Inc. (NASDAQ:SGEN) presented initial Phase 2 data for ADCETRIS in combination with immunotherapy pembrolizumab in metastatic non-small cell lung cancer and metastatic cutaneous melanoma at the Society for Immunotherapy of Cancer Annual Meeting. The company also shared preclinical data for a novel antibody-drug conjugate SGN-35T. The combination of ADCETRIS and a PD-1 inhibitor showed promising results, supporting continued research. Seagen plans to begin enrolling patients in a phase 1 clinical trial for SGN-35T soon.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:12 pm

EA

EA Sports has launched its World Rally Championship (WRC) game worldwide. The game features new dynamic handling technology that allows players to push their limits and race for WRC glory.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:11 pm

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) has presented positive safety and feasibility data from a Phase 1 trial of its investigational class C toll-like receptor-9 (TLR9) agonist, SD-101, for pancreatic adenocarcinoma at the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting. The data from the PERIO-03 clinical trial indicates that the Pressure-Enabled Drug Delivery (PEDD) method resulted in modulation of the tumor microenvironment. The trial revealed no serious grade 3/4 adverse events related to treatment in three patients who received SD-101 via retrograde venous infusion PEDD at the lowest dose level.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:11 pm

XAIR

Beyond Cancer, an affiliate of Beyond Air, Inc. (NASDAQ:XAIR), presented first-in-human clinical data for ultra-high concentration nitric oxide (UNO) therapy in solid tumors at the Society for Immunotherapy of Cancer 2023 Annual Meeting. The Phase 1 study showed promising safety profile and clear evidence of immune system activation. Additional Phase 1 data for UNO is expected in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:10 pm

MOLN

Molecular Partners AG (NASDAQ:MOLN) has presented positive data from its ongoing Phase 1 trial of MP0317 monotherapy in patients with advanced solid tumors at the 2023 SITC Annual Meeting. The data shows that MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment. The monotherapy also shows a favorable safety profile up to the highest planned doses. The company expects to share final results of this study in 2024.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

TBIO

Telesis Bio has announced the commercial release of its cell-free amplification kit for the generation of transfection-scale DNA. This product is expected to significantly enhance the company's product portfolio.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

CDTX

Cidara Therapeutics, Inc. (NASDAQ:CDTX) has presented new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data shows the potential of CBO421 to inhibit tumor growth as both a monotherapy and in combination with PD-1 therapies. The company plans to advance this candidate into clinical trials for the treatment of solid tumors.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

XNCR

Xencor has presented preclinical data from multiple XmAb research programs at the SITC Annual Meeting. The company is conducting a Phase 1 study of XmAb808 in patients with advanced solid tumors. Xencor also engineered stabilized, potency-modulated IL-18 cytokines fused to an XmAb heterodimeric Fc domain with Xtend™ Fc technology for longer half-life (IL18-Fc). Further, Xencor's XmAb natural killer cell engagers (NKEs) are multifunctional antibodies that target multiple activating receptors on the surface of NK cells and bind to tumor-associated antigens.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:09 pm

INKT

MiNK Therapeutics, Inc. (NASDAQ:INKT) presented new data on its agenT-797 therapy for solid tumor cancers at the Society for Immunotherapy of Cancer's annual meeting. The therapy showed clinical responses and long-term persistence without toxic pre-conditioning. AgenT-797 is advancing in a randomized phase 2 trial in 2L gastric cancer. The company also plans to launch a randomized phase 2 trial in 2L gastric cancer by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 4:08 pm